Biological
BRL-301
BRL-301 is a biological therapy with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph not_applicable
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)
Highest Phase Reached
UnknownTrial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Enrolling by invitation1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
N/A
Trials by Phase
N/A3 (100.0%)
Trials by Status
recruiting267%
enrolling_by_invitation133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingnot_applicable
Universal CAR-T Cell Therapy for NHL
NCT07248163
enrolling_by_invitationnot_applicable
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
NCT05859997
recruitingnot_applicable
Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus
NCT05988216
Clinical Trials (3)
Showing 3 of 3 trials
NCT07248163Not Applicable
Universal CAR-T Cell Therapy for NHL
NCT05859997Not Applicable
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
NCT05988216Not Applicable
Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3